Jim Simons
PMCB icon

Jim Simons’s PharmaCyte Biotech PMCB Stock Holding History

Jim Simons’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6K Sell
56,500
-37,536
-40% -$28.7K ﹤0.01% 3127
2025
Q4 		$68.1K Buy
94,036
+14,036
+18% +$12.6K ﹤0.01% 3059
2025
Q3 		$77.6K Buy
80,000
+30,200
+61% +$30.1K ﹤0.01% 3289
2025
Q2 		$54.3K Buy
49,800
+300
+0.6% +$335 ﹤0.01% 3383
2025
Q1 		$61.9K Buy
49,500
+200
+0.4% +$325 ﹤0.01% 3268
2024
Q4 		$77.4K Sell
49,300
-400
-0.8% -$690 ﹤0.01% 3320
2024
Q3 		$94.9K Buy
49,700
+1,200
+2% +$2.23K ﹤0.01% 3266
2024
Q2 		$95.1K Buy
48,500
+4,700
+11% +$10.1K ﹤0.01% 3192
2024
Q1 		$104K Buy
43,800
+5,700
+15% +$12.3K ﹤0.01% 3360
2023
Q4 		$82K Buy
38,100
+5,200
+16% +$11.3K ﹤0.01% 3353
2023
Q3 		$69K Buy
32,900
+7,026
+27% +$17.9K ﹤0.01% 3330
2023
Q2 		$74K Buy
+25,874
New +$77.6K ﹤0.01% 3535

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Jim Simons's PMCB Position: Q1 2026 in Review

Jim Simons reduced its PharmaCyte Biotech (PMCB) stake by 40% in Q1 2026, selling an estimated $28.7K and leaving 56,500 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3127.

Jim Simons first reported a position in PMCB in Q2 2023 and has held it in 12 quarters since. The position peaked at $104K in Q1 2024. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Jim Simons held 56,500 shares of PharmaCyte Biotech worth $37.6K as of Q1 2026.
  • Jim Simons sold 37,536 PharmaCyte Biotech shares in Q1 2026, an estimated $28.7K.
  • PharmaCyte Biotech made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #3127 holding.
  • Jim Simons first reported a position in PharmaCyte Biotech in Q2 2023 and has held it in 12 quarters since.
  • Jim Simons's PharmaCyte Biotech position peaked at $104K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.